AB-FUBINACA

AB-FUBINACA 

AB-FUBINACA  is a drug that acts as a potent agonist for the cannabinoid receptors, with Kᵢ values (of 0.9 nM at CB₁ and 23.2 nM at CB₂,) and EC₅₀ values of (1.8 nM at CB₁ and 3.2 nM at CB₂).
(N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-flinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. However, AB-FUBINACA is orally active when dissolved in a lipid, which can increase the duration significantly. Nevertheless, it is insoluble in water but dissolves in ethanol and lipids.

MORE ABOUT AB-FUBINACA

AB-FUBINACA, or N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide, is a synthetic indazole cannabinoid drug as it contains a substitute of indazole core. A 4- is a substitute of fluorophenyl group. However, it bounds to the indazole core through a methyl group at R1.  Notwithstanding, indazole is a substitute at R3 with a carboxamide group. The terminal amine of carboxamide bonds to a substitute propyl chain. They also bond with an aminocarbonyl group at R1 and a methyl group at R2.

Although this substance is still under study, from analysis of the structure, the presumption is that AB-FUBINACA has a similar binding profile. Neverthless, it is similar to that of other cannabinoids and matches many of the in vivo properties of Δ9-THC. AB-Fubinaca. As with the compounds within cannabis, AB-FUBINACA exhibits its range of effects via full agonism. The agonism is of both the CB1 and CB2 cannabinoid receptors, with some selectivity for CB2. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive. AB-Fubinaca

Unlike cannabis, the chronic abuse of synthetic cannabinoids ties in line with multiple deaths and more dangerous side effects and toxicity in general. It was originally developed by Pfizer in 2009 as an analgesic medication,[1] but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan[2]. However,  along with a related compound AB-PINACA which is also trending in the market. AB-Fubinaca